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Abstract
Background—Prediabetes affects 1 in 3 Americans. Both intensive lifestyle intervention and 
metformin can prevent or delay progression to diabetes. Over the past decade, lifestyle 
interventions have been translated across various settings, but little is known about the translation 
of evidence surrounding metformin use.
Objective—To examine metformin prescription for diabetes prevention and patient 
characteristics that may affect metformin prescription.
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Design—Retrospective cohort analysis over a 3-year period.
Setting—Employer groups that purchased health plans from the nation’s largest private insurer.
Participants—A national sample of 17 352 working-age adults with prediabetes insured for 3 
continuous years between 2010 and 2012.
Measurements—Percentage of health plan enrollees with prediabetes who were prescribed 
metformin.
Results—Only 3.7% of patients with prediabetes were prescribed metformin over the 3-year 
study window. After adjustment for age, income, and education, the predicted probability of 
metformin prescription was almost 2 times higher among women and obese patients and more 
than 1.5 times higher among patients with 2 or more comorbid conditions.
Limitation—Missing data on lifestyle interventions, possible mis-classification of prediabetes 
and metformin use, and inability to define eligible patients exactly as defined in the American 
Diabetes Association guidelines.
Conclusion—Evidence shows that metformin is rarely prescribed for diabetes prevention in 
working-age adults. Future studies are needed to understand potential barriers to wider adoption of 
this safe, tolerable, evidence-based, and cost-effective prediabetes therapy.
Primary Funding Source—Centers for Disease Control and Prevention (Division of Diabetes 
Translation) and the National Institute of Diabetes and Digestive and Kidney Diseases.
Diabetes prevention is an important national health goal. The number of persons with 
prediabetes, which has increased to more than 1 in 3 U.S. adults (1, 2), shows the urgent 
need for effective action leading to prevention. However, the means through which diabetes 
prevention can best be achieved on an individual as well as population level remains 
unclear.
For more than 10 years, the literature has provided strong evidence to support the use of 
both intensive lifestyle intervention and metformin to help prevent diabetes among persons 
at increased risk because of prediabetes. In 2002, the DPP (Diabetes Prevention Program) 
showed that lifestyle intervention and metformin reduced the incidence of diabetes by 58% 
and 31%, respectively, compared with placebo over 2.8 years (3). These findings were 
supported by several other randomized studies and were shown to persist for up to 10 years 
in longitudinal observational studies (3–8). The 16-week intensive lifestyle intervention in 
the DPP was associated with the largest cumulative risk reduction, which prompted many 
translational studies (9–11). However, efforts to translate DPP-based lifestyle interventions 
have been associated with various levels of uptake and reach (9–12).
In contrast, little is known about the translation of the evidence supporting metformin use to 
prevent diabetes. Such evidence is strongest for those at increased risk for progression to 
diabetes, including persons younger than 60 years, those with a body mass index (BMI) of 
35 kg/m2 or greater, or those with a history of gestational diabetes (3, 6, 8, 13). Beginning in 
2008, the annual “Standards in Medical Care in Diabetes” guidelines from the American 
Diabetes Association recommended metformin use for diabetes prevention in patients at 
very high risk who meet the aforementioned criteria and added that metformin use “may be 
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considered” in those with impaired glucose tolerance, impaired fasting glucose level, or a 
hemoglobin A1c level of 5.7% to 6.4% (13).
Despite inclusion in national guidelines for more than 6 years (13) and proven long-term 
tolerability, safety, and cost-effectiveness (14), the prescription of metformin in the real-
world clinical approach to diabetes prevention remains unclear. The only published study to 
include incidence of metformin use among patients with prediabetes found that fewer than 
0.1% were prescribed metformin (15). However, these data were collected from an 
integrated health delivery system that may not accurately reflect wider practice patterns and 
were reported for only 1 time point within 6 months of prediabetes identification. Further, 
this study began in 2006, which was 2 years before metformin use was first emphasized in 
national guideline recommendations for diabetes prevention (13, 16).
The goal of our analysis was to characterize metformin prescriptions in a sample of insured, 
working-age adults with prediabetes from all 50 states. We also explored the association 
between specific patient characteristics and the receipt of metformin. We hypothesized that 
despite the existence of practice guidelines supporting its use, metformin is rarely prescribed 
for diabetes prevention.
Methods
We examined data from 2010 to 2012 from United-Healthcare (UHC), the nation’s largest 
private insurer (17), using a retrospective cohort analysis of metformin prescription among 
adults with prediabetes over a 3-year period.
Setting and Participants
Participants were employees and covered dependents aged 19 to 58 years at baseline and 
enrolled in UHC benefit plans for 3 continuous years. The study window was from 2010 to 
2012. Data from year 1 (2010) were used to define the sample with prediabetes and exclude 
persons with diabetes.
All participants had diagnoses of prediabetes at year 1, defined as any of the following: 2 or 
more International Classification of Diseases, Ninth Revision (ICD-9), diagnostic codes of 
790.2× from an inpatient or out-patient claim; last hemoglobin A1c level of 5.7% to 6.4%; 
last fasting plasma glucose level of 5.55 to 6.94 mmol/L (100 to 125 mg/dL); or last 2-hour 
plasma glucose level of 7.77 to 11.04 mmol/L (140 to 199 mg/dL) on an oral glucose 
tolerance test. Patients with a diagnosis of diabetes in year 1 were excluded from the sample. 
Diabetes was defined as any of the following: 1 or more ICD-9 diagnostic codes of 250.xx 
from an inpatient or outpatient claim; hemoglobin A1c level of 6.5% or greater; fasting 
plasma glucose level greater than 6.94 mmol/L (>125 mg/dL); 2-hour plasma glucose level 
of 11.1 mmol/L (200 mg/dL) or greater on an oral glucose tolerance test; or 1 or more 
prescription claims for insulin or an antiglycemic medication other than metformin.
Data from 183 UHC employer groups with sufficient administrative and laboratory data to 
identify employees with prediabetes and pharmacy claims over the 3-year study window 
were available as part of a larger design study on health benefits (Appendix, available at 
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www.annals.org) (18) (Moin T, Steers WN, Ettner SL, Duru OK, Turk N, Neugebauer R, et 
al. The association of a diabetes-specific health plan with ER and in-patient hospital 
utilization: a natural experiment for translation in diabetes [NEXT-D]. In preparation.). 
These 183 groups were identified from a larger set of 1357 employer groups that purchased 
benefit plans from UHC between 2009 and 2010. Compared with the larger pool of 1174 
groups, these 183 groups tended to be larger, had slightly higher proportions of patients with 
chronic conditions, and had slightly more Hispanic employees but were similar in terms of 
other racial/ethnic distributions, mean employee income, proportion of female employees, 
and proprietary estimates of benefit generosity provided by the health plan.
Among the 183 employer groups, there were 35 910 employees or covered dependents who 
were continuously enrolled with UHC for 3 years and had prediabetes in year 1. We 
excluded patients with a history of diabetes in year 1 (n = 9606), those who were not aged 
19 to 58 years in year 1 (n = 8006) because national guidelines highlight evidence for 
metformin use in patients younger than 60 years, and women with a history of the polycystic 
ovary syndrome (n = 258) because metformin can be prescribed for reasons other than 
diabetes prevention in this group (for example, oligomenorrhea and infertility) (19–21). We 
also excluded those who were pregnant (n = 426) because metformin is classified under U.S. 
Food and Drug Administration pregnancy category B, as well as those with an elevated 
creatinine level (defined as ≥132.6 μmol/L [1.5 mg/dL] for men and ≥123.8 μmol/L [1.4 
mg/dL] for women [n = 262]) because renal insufficiency is a contraindication to metformin 
use. The final analytic sample comprised 17 352 patients with prediabetes (Figure). We then 
identified a dominant provider for each patient by using the most frequent National Provider 
Identifier number in inpatient or out-patient claims during the 3-year study window.
Primary Outcome
The primary outcome was a dichotomous indicator for metformin prescription among adult 
employees and covered dependents with prediabetes based on UHC prescription claims data. 
Metformin prescription was defined as any prescription claim for metformin in the 3-year 
study window. For patients who developed diabetes during years 2 and 3 (2011 and 2012), 
only metformin prescriptions before diabetes identification were included.
Covariates
The age and sex of patients were obtained from UHC eligibility files. Education, income, 
and race/ethnicity were estimated by UHC using a proprietary algorithm that incorporated 
geographic locators (that is, ZIP codes of record); consumer survey information; census 
income distribution data; and first, middle, and last names. Comorbid conditions, including 
history of the polycystic ovary syndrome, pregnancy, gestational diabetes, and obesity (BMI 
≥30 kg/m2), were defined as 1 or more ICD-9–related diagnoses from inpatient or outpatient 
claims.
Statistical Analysis
We used a multivariate logistic regression model to test the association between specific 
patient characteristics and metformin prescription during the 3-year study window. We 
adjusted the model for age, sex, race, income, education, diagnosis of obesity, and number 
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of comorbid conditions at baseline. Age and obesity were included in the model because the 
evidence for metformin use is greatest in those younger than 60 years or with a BMI greater 
than 35 kg/m2. We included race because certain groups (such as African Americans) have a 
higher risk for diabetes, and this may affect willingness or motivation to prescribe 
metformin for prevention. Sex was included because women are more likely to use health 
services overall, which may affect the likelihood of receiving a prescription, such as 
metformin. The number of comorbid conditions may also affect the use of health services 
and willingness to use metformin (that is, willingness may be higher for one who is already 
accustomed to taking medications but lower for one who has never been prescribed 
medications in the past). Last, we included estimates of income and education because these 
are proxies for health literacy and financial resources. We conducted multiple imputation by 
a chained equations approach to address missing data in the race/ethnicity (5%), education 
(1%), and income (8%) estimates. The resulting estimations were combined across 10 
imputed data sets by using Rubin rules (22, 23). Multiple imputation was done in STATA 
using the user-written “ice” command, and the “mi estimate” command was then used to 
estimate and combine the primary outcome of interest across 10 imputed data sets. The 
STATA “margins” command was used to obtain predicted probabilities of metformin 
prescription over the 3-year study window.
The academic team members analyzed all data independently and retained sole authority 
over all publication-related decisions throughout the study. All analyses were done using 
SAS, version 9.3 (SAS Institute), and STATA, version 12.1 (StataCorp). The study was 
approved by the Institutional Review Board at the University of California, Los Angeles.
Role of the Funding Source
This study was jointly funded by the Centers for Disease Control and Prevention (Division 
of Diabetes Translation) and the National Institute of Diabetes and Digestive and Kidney 
Diseases as part of the Natural Experiments for the Translation of Diabetes (NEXT-D) study 
(grant number U58DP002722-05). The funding sources had no role in the design, conduct, 
or reporting of the study or the decision to submit the manuscript for publication.
Results
We analyzed data from 17 352 adults aged 19 to 58 years with prediabetes who were 
continuously enrolled in UHC benefit plans from 2010 to 2012. Forty-five percent were 
women, and 65% were white (Table 1). A total of 13 743 dominant providers submitted visit 
claims for this cohort during the 3-year study window. Only 3.7% (n = 647) of patients had a 
prescription claim for metformin during the study (Appendix Table 1, available at 
www.annals.org, provides the prevalence of metformin prescription by relative distribution 
of prediabetes inclusion criteria). However, among the smaller subset of patients with a BMI 
greater than 35 kg/m2 (n = 391) or gestational diabetes (n = 121)—the group for which the 
American Diabetes Association guideline places the most emphasis on treating prediabetes 
with metformin—the prevalence of metformin prescription was 7.8%.
We found that the adjusted predicted probability of metformin prescription was almost twice 
as high among women (4.8%) than among men (2.8%) ( P < 0.001) and among obese 
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patients (6.6%) compared with nonobese patients (3.5%) (P < 0.001) and was 1.5 times as 
high among patients with 2 or more comorbid conditions (4.2%) versus those with none 
(2.8%) (P = 0.001) (Table 2).
We did 4 sensitivity analyses (Appendix Table 2, available at www.annals.org). First, we 
applied a more stringent diagnostic criterion of 2 or more ICD-9 codes to define diabetes. 
With this approach, the prevalence of metformin prescription was 4.8% over 3 years, but 
there were no changes in the significance of the association of metformin prescription with 
patient-level characteristics. Second, we included metformin prescription before 
identification of diabetes in all 3 years (vs. years 2 and 3), and this increased the prevalence 
of metformin prescription to 4.4% over 3 years. Third, we included women with a history of 
the polycystic ovary syndrome, which also increased the prevalence of metformin 
prescription to 4.4% over 3 years. Last, we tried to address the lack of available data on the 
use of lifestyle interventions. Although systematic data on uptake of DPP-based lifestyle 
interventions were not available across all plans included in this analysis, the uptake of DPP 
lifestyle interventions has ranged from 2% to 25% for health plans that contract with UHC 
to provide these programs (Bandapati S, Chapman-Smith L, Keckhafer A. Personal 
communication). Thus, we conservatively assumed that 25% of the entire sample was 
participating in lifestyle interventions, which would imply that the prevalence of metformin 
prescription was still only 5.0% in the remaining sample.
Discussion
Our study of a national sample of insured, working-age adults found that only 3.7% of 
patients with prediabetes (1 in 27) were prescribed metformin over a 3-year period. The 
prevalence of metformin prescription was higher (7.8%) among a smaller subset of patients 
with a history of gestational diabetes or a BMI greater than 35 kg/m2. However, this means 
that fewer than 1 in 12 of these high-risk patients, specifically identified by national 
guidelines, received metformin. The predicted probability of metformin prescription was 
higher for women, obese patients, and those with more comorbid conditions.
Our findings highlight concern about translation of decade-old evidence supporting the use 
of metformin for diabetes prevention. Although we observed a metformin prescription 
prevalence of 3.7%, which is higher than the prevalence of less than 0.1% previously 
reported by Schmittdiel and colleagues (15), it still represents underuse of a highly effective 
prevention strategy. Schmittdiel and colleagues only reported metformin use within 6 
months of prediabetes identification, but our study examined the prevalence of metformin 
prescription over a 3-year study window. In addition, Schmittdiel and colleagues examined 
electronic medical record data between 2006 and 2010, but our study is, to our knowledge, 
the first to specifically examine the prevalence of metformin prescription after the American 
Diabetes Association guideline changes in 2008 and the first to include a national sample of 
working-age adults younger than 60 years, in whom indications for metformin use may be 
strongest (24).
From a public health perspective, the lack of translation of a safe, evidence-based therapy 
for a highly prevalent condition is problematic. Studies have shown that lifestyle 
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intervention is cost-effective, whereas metformin can be marginally cost-saving (25). Our 
study targeted insured persons with prediabetes who were receiving care, and metformin use 
of 3.7% seems especially low for this group. It is unlikely that many patients in our cohort 
were participating in intensive lifestyle programs. If we assumed that 25% of patients in the 
sample were actively participating in lifestyle interventions, the prevalence of metformin 
prescription was still only 5.0% in the remaining sample. The ideal scenario would be for 
everyone at risk for diabetes to pursue lifestyle interventions. However, given the resources 
needed to effectively deliver intensive lifestyle programs and the variable uptake reported in 
translational studies (9–12), patients should, at a minimum, be educated about the potential 
benefits of metformin and should, ideally, also be offered this option as preventive treatment 
for diabetes. This protocol may be feasible to implement on a wide scale given its relative 
accessibility, safety, and cost-effectiveness (14, 25, 26), and it is accessible under most 
prescription drug plans. It may also be a particularly attractive option for persons with 
significant time commitments that make lifestyle change challenging and may allow them to 
fully engage in evidence-based diabetes prevention strategies.
The reasons for low metformin use are not entirely clear, and future studies should examine 
an array of patient-, provider-, and organization-level factors that may contribute to 
underuse. For providers, barriers may include lack of knowledge about the DPP or related 
evidence. Even when the randomized clinical trial evidence is fully realized, there is little 
guidance for the application of these findings in real-world settings. Metformin is not 
approved by the U.S. Food and Drug Administration for prediabetes, which may increase 
hesitancy to prescribe it “off label” in this context (27). We identified 13 743 dominant 
physicians for this cohort of 17 352 patients, so metformin underuse is probably widespread 
among physicians rather than being limited to a small group of providers caring for many 
patients.
In addition, both providers and patients may place higher priority on other medical needs or 
be reluctant to “medicalize” prediabetes (15). Patients and providers may also lack 
awareness of prediabetes, specifically the natural disease course that can result in incident 
diabetes in 30% of patients within 3 to 4 years (28) and the associated risks (for example, 
microvascular complications) (3). However, obesity is a well-recognized risk factor for 
diabetes, and this may have contributed to the increased probability of metformin 
prescription seen in this group. Patients with more comorbid conditions may also be at 
increased risk for diabetes. They are also probably more accustomed to taking daily 
medications, so the threshold to start metformin (that is, to add 1 more pill) may be lower or 
they may be more motivated to prevent another comorbid condition. These observations, 
although based on a small sample, suggest that there is awareness of risk on some level, but 
further studies should examine how prediabetes risk perception and awareness affect patient 
and provider approaches to management. In general, further studies are also needed to fully 
understand all possible barriers surrounding metformin use in patients at highest risk so that 
successful interventions can be developed.
To reap the full public health benefits of the considerable research investment in diabetes 
prevention to date (29), we need truly informed and shared decision making between 
patients and providers in real-world settings. Optimal prediabetes management should be 
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based on individualized risk assessment and patient preferences. The evidence for 
metformin use is strongest for patients younger than 60 years, those with a BMI greater than 
35 kg/m2, or those with a history of gestational diabetes (13). Expert panels have also 
advocated that metformin use be considered in patients with an impaired fasting glucose 
level and impaired glucose tolerance if they also have a family history of diabetes in first-
degree relatives, elevated triglyceride levels, reduced high-density lipoprotein cholesterol 
levels, hypertension, or more severe or progressive hyperglycemia (either a hemoglobin A1c 
level >6.0% or progression of an underlying disease, as evidenced by an increase in fasting 
plasma glucose, hemoglobin A1c, or 2-hour postprandial glucose level) (30). Potential 
strategies to increase awareness and promote informed decision making among this at-risk 
population could include clinical decision-making tools, physician-directed and 
performance-based incentive programs, or media campaigns to increase public awareness of 
prediabetes and its consequences if left untreated.
Our findings should be interpreted with a few limitations in mind. First, we did not have 
access to data on participation in lifestyle interventions, which are considered first-line 
therapy for diabetes prevention. However, a sensitivity analysis using estimates of uptake of 
lifestyle interventions did not substantially change our estimated prevalence of metformin 
prescription. Second, because this was a claims-based analysis, possible misclassification of 
prediabetes and metformin use may have occurred (for example, metformin use may not 
have been captured if no prescription claim was generated because an enrollee paid out of 
pocket or if a prescription was written by a provider but never filled by the patient). Third, 
our analysis focused on commercially insured adults and may not be generalizable to 
uninsured or older patients. However, our focus on working-age adults is important because 
prediabetes affects more than 1 in 3 adults older than 20 years and the evidence for 
metformin use is strongest for those younger than 60 years (3, 6, 30). Last, our definition of 
eligible patients differed from the definition in the American Diabetes Association national 
guidelines (13). Underdetection of women who may have had gestational diabetes more than 
3 years ago and lack of actual BMI measurements make estimates in these high-risk groups 
more challenging. However, the prevalence of metformin prescription was only 7.8% in the 
small subset of patients identified as having a history of gestational diabetes or a BMI 
greater than 35 kg/m2 based on claims data. Thus, fewer than 1 in 12 high-risk patients 
specifically identified by national guidelines received metformin, which suggests room for 
improved translation of the evidence surrounding metformin use for diabetes prevention.
In conclusion, our findings indicate that metformin is rarely prescribed for diabetes 
prevention despite a strong evidence base in the literature for more than 10 years and 
inclusion in practice guidelines for more than 6 years. This is a potential gap in the approach 
to prediabetes management and a significant missed opportunity for diabetes prevention in 
patients at highest risk. Further studies are needed to understand the root causes of this 
potential gap and possible interventions to help promote the translation of known evidence 
into real-world practice.
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Data from 183 UHC employer groups were available as part of a larger design study on 
health benefits constructed to evaluate an innovative, disease-specific health plan known as 
the Diabetes Health Plan (DHP). The goal of the larger study was to examine the association 
of the DHP with outcomes, such as medication adherence and utilization of health services, 
by comparing data from employer groups that purchased the DHP with comparable 
employer groups that purchased standard benefit plans during the same time.
Among the employer groups purchasing standard benefit plans, 1357 contracted with UHC 
for pharmacy benefits and were in similar industries and of similar size compared with 
employer groups that had purchased the DHP. Because randomization was not possible in 
this natural experiment, we analyzed an employer-level propensity score to identify 
employer groups offering standard plans that were most comparable to DHP groups (20, 21). 
We compared groups on the basis of employer size, mean income, proportion of female 
employees, proportion of employees with a chronic condition, and proprietary information 
on the generosity of benefits provided by the health plan. Propensity score modeling yielded 
339 groups most comparable to the DHP groups (that is, within the region of common 
support) (22, 23). Among these, 233 had sufficient administrative and laboratory data to 
identify employees with prediabetes. We excluded groups that did not have available 
pharmacy claims over the entire 3-year study window (n = 13), were in the Mid-Atlantic 
region (where no DHP employer groups were located [n = 22]), had more than 90% of 
employees enrolled in high-deductible health plans (n = 8), had fewer than 20 employees 
with diabetes or prediabetes (n = 2), or had terminated their contract with UHC within the 
study period (n = 5), which left a final sample of 183 employer groups as the control.
Our sample can probably be generalized to larger employer groups (>500 employees), but 
we have no reason to believe that the prevalence of metformin prescriptions would vary by 
size of an employer group.
Appendix Table 1
Prevalence of Metformin Prescription by Relative Distribution of Prediabetes Inclusion 
Criteria*






≥2 ICD-9 codes of 790.2x 2361 243 10.3
Hemoglobin A1c level of 5.7%–6.4% 5459 268 4.9
Fasting plasma glucose level of 5.55 to 6.94 mmol/L 
(100–125 mg/dL)
11 516 274 2.4
2-h plasma glucose level of 7.77 to 11.04 mmol/L 
(140–199 mg/dL) on oral glucose tolerance test
50 7 14.0
Any 17 352 647 3.7
ICD-9 = International Classification of Diseases, Ninth Revision.
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The last laboratory values in a given year were used, and some patients met >1 inclusion criterion; therefore, the sum of 
the values in the “Patients Identified” column is >17 352, and the sum of the values in the “Patients Prescribed Metformin” 
column is >647.
Appendix Table 2
Results of Sensitivity Analyses








Apply a diabetes definition with ≥2 ICD-9 
codes (250.xx) during the 3-y study 
window*
868 18 114 4.8
Include metformin prescriptions before 
diabetes identification throughout 3-y study 
window
820 18 687 4.4
Include women with history of PCOS (n = 
227)
123 received metformin; 
123 + 647 = 770
17 579† 4.4
Assume 25% of patients in cohort are 
participating in lifestyle interventions (n = 
4338)
647 (unchanged) 13 014 5.0
Results of main analyses for comparison 647 17 352 3.7
ICD-9 = International Classification of Diseases, Ninth Revision; PCOS = the polycystic ovary syndrome.
*
Used to exclude patients with diabetes in year 1 (2010) and those who developed diabetes in years 2 and 3 (2011 and 
2012). For patients who developed diabetes during years 2 and 3, only metformin prescriptions before diabetes 
identification were included.
†
There were 258 women with PCOS, but we excluded the 31 who were also pregnant during the 3-y study window, leaving 
227 eligible women with PCOS for the sensitivity analysis (17 352 + 227 = 17 579 [new denominator]).
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Randomized trial evidence shows that lifestyle changes or metformin can delay the 
progression of prediabetes to overt diabetes. Efforts to modify lifestyle interventions to 
include diabetes prevention have had various levels of uptake, but little is known about 
the uptake of metformin for this purpose.
Contribution
This study examined metformin use in a large sample of insured U.S. adults with 
prediabetes and found that only 3.7% were prescribed metformin over a 3-year period.
Implication
Metformin seems to be used infrequently to prevent the development of overt diabetes in 
patients with prediabetes.
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The study window was 3 y (2010 to 2012). Prediabetes was defined as any of the following: 
≥2 ICD-9 diagnostic codes of 790.2× from an inpatient or outpatient claim, last hemoglobin 
A1c level of 5.7% to 6.4%, last fasting plasma glucose level of 5.55 to 6.94 mmol/L (100 to 
125 mg/dL), or last 2-h plasma glucose level of 7.77 to 11.04 mmol/L (140 to 199 mg/dL) 
on an oral glucose tolerance test. Pregnancy was defined as ≥1 pregnancies during the study. 
Elevated creatinine level was defined as ≥132.6 μmol/L (≥1.5 mg/dL) for men and ≥123.8 
μmol/L (≥1.4 mg/dL) for women. ICD-9 = International Classification of Diseases, Ninth 
Revision; PCOS = the polycystic ovary syndrome.
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Table 1
Baseline (2010) Demographic Characteristics of Patients With Prediabetes Continuously Insured Over 3 
Years*
Characteristic Enrollees With Prediabetes (n = 17 352), n (%)
Female 7884 (45)
Age group
 19 to <35 y 1385 (8)
 35 to <45 y 4062 (23)
 45 to <55 y 8068 (47)
 55–58 y 3837 (22)
Race/ethnicity
 White 11 209 (65)
 Hispanic 2557 (15)
 African American 1635 (9)
 Asian 1021 (6)
 Other 64 (0)
 Missing 866 (5)
Annual household income
 <$30 000 593 (3)
 $30 000–$49 000 2529 (15)
 $50 000–$74 000 4331 (25)
 ≥$75 000 8454 (49)
 Missing 1445 (8)
Education level
 High school or less 4363 (25)
 Some college 9076 (52)
 Bachelor’s degree or higher 3750 (22)
 Missing 163 (1)
Obesity† 1341 (8)
Number of comorbid conditions
 0 4115 (24)
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Characteristic Enrollees With Prediabetes (n = 17 352), n (%)
 1 5440 (31)
 2 4688 (27)
 ≥3 3109 (18)
*
Race/ethnicity, education, and income were estimated by a proprietary algorithm. We conducted multiple imputation by a chained equations 
approach to address missing data in the race/ethnicity, education, and income estimates.
†
International Classification of Diseases, Ninth Revision, classification for body mass index ≥30 kg/m2.













Moin et al. Page 17
Table 2
Adjusted Predicted Probability of Metformin Prescription Over the 3-Year Study Window*
Characteristic Predicted Probability of Metformin Prescription (n = 17 352), % P Value
Sex
 Male 2.8 (reference)
 Female 4.8 <0.001
Age group
 19 to <35 y 3.5 (reference)
 35 to <45 y 3.8 0.65
 45 to <55 y 3.8 0.70
 55–58 y 3.6 0.91
Race/ethnicity
 White 3.8 (reference)
 Hispanic 3.8 0.94
 African American 2.9 0.060
 Asian 3.2 0.36
 Other 8.2 0.089
Annual household income
 <$30 000 2.5 (reference)
 $30 000–$49 000 3.8 0.118
 $50 000–$74 000 4.1 0.052
 ≥$75 000 3.6 0.156
Education level
 High school or less 3.8 (reference)
 Some college 3.6 0.54
 Bachelor’s degree or higher 3.9 0.94
Obesity†
 No 3.5 (reference)
 Yes 6.6 <0.001
Number of comorbid conditions
 0 2.8 (reference)
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Characteristic Predicted Probability of Metformin Prescription (n = 17 352), % P Value
 1 3.4 0.119
 2 4.2 0.001
 ≥3 4.9 <0.001
*
Adjusted for sex, age, race/ethnicity, income, education, diagnosis of obesity, and number of comorbid conditions at baseline. Race/ ethnicity, 
education, and income were estimated by a proprietary algorithm. We conducted multiple imputation by a chained equations approach to address 
missing data in the race/ethnicity (5%), education (1%), and income (8%) estimates.
†
International Classification of Diseases, Ninth Revision, classification for body mass index ≥30 kg/m2.
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